Dr. Moses On Ongoing Trials in mHSPC

Partner | Cancer Centers | <b>Vanderbilt-Ingram Cancer Center</b>

Kelvin Alexander Moses, MD, PhD, discusses ongoing clinical trials in metastatic hormone-sensitive prostate cancer.

Kelvin Alexander Moses, MD, PhD, associate professor in the Department of Urology at Vanderbilt University Medical Center, discusses ongoing clinical trials in metastatic hormone-sensitive prostate cancer (mHSPC).

Combination strategies are currently under investigation, says Moses. Additionally, checkpoint inhibitors are being explored in men with specific alterations, such as BRCA mutations.

During the 2019 OncLive® State of the Science Summit™ on Genitourinary Malignancies, Kirk A. Keegan, MD, MPH, spoke about advanced diagnostic imaging modalities, says Moses. Advanced imaging may allow for earlier detection and intervention of metastatic prostate cancer. However, further research is needed to determine if there is a comparable survival advantage with earlier treatment exposure as with current approved agents, concludes Moses.